الفهرس 
Introduction and Aim of the WorkOnly 14 pages are availabe for public view
 |  | from | 135 |  |  |
| | | from | 135 | | |
Abstract
Aim of the work
Is to estimate the serum thrombopoitin (TPO) level in patients with chronic liver diseases, its correlation with the circulating platelet count and the severity of the liver disease.
Conclusion
In conclusion this study proved the relationship between serum TPO concentration, number of platelet counts and the severity of the liver disease. The level of circulating platelets full progressively as the degree of hepatic fibrosis increases.
Serum thrombopoitin (TPO) levels are increased above control levels in patients with different stages of chronic hepatitis as the degree of fibrosis progresses to cirrhosis, thrombopoitin (TPO) levels fall. While serum (TPO) levels increase in patients with liver cirrhosis with HCC due to production of thrombopoietin by hepatoma cells, in patients with more severe hepatic fibrosis, there is inappropriate thrombopoitin (TPO) response to decreased platelet levels, which correlates with decreased liver synthetic function, as assessed by prothrombin time (PT). These results suggest that impaired synthesis of thrombopoitin (TPO) by the decreased liver may contribute to the development of thrombocytopenia in chronic liver disease.
These data suggest that thrombocytopenia associated with liver disease may be attributable, at least in part to inadequate TPO production in the failing liver.
Recommendation
TPO administration to patients with liver cirrhosis may be helpful in reducing the risk bleeding in certain situations such as during surgery as the injection of TPO in vivo induces an increase in platelet number, and TPO can also potentiate platelet activity in vitro studies.